Yahoo
    NasdaqCM - Nasdaq Real Time Price USD

    VivoSim Labs, Inc. (VIVS)

    0.1549 +0.0003 (+0.19%)
    As of 9:40:05 AM EST. Market Open.
    Loading Chart for VIVS
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

    VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
    GlobeNewswire 12d ago
    VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

    VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
    GlobeNewswire 26d ago
    VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)

    VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)
    InvestorsHub 3mo ago
    VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

    VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
    GlobeNewswire 3mo ago
    VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

    VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
    GlobeNewswire 3mo ago
    VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth

    VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth
    InvestorsHub 3mo ago
    VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

    VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
    GlobeNewswire 3mo ago
    VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

    VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
    GlobeNewswire 4mo ago
    VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

    VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
    GlobeNewswire 6mo ago
    VivoSim Announces Pricing of up to a $4 Million Public Offering

    VivoSim Announces Pricing of up to a $4 Million Public Offering
    GlobeNewswire 6mo ago
    Top Midday Gainers

    Top Midday Gainers
    PREMIUM
    MT Newswires 8mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: